Figure 1

2–6-week run-in period

6 weeks
2 weeks

Screening
Randomization
End of 6-week treatment period

Crossover study – 4 treatments given in random order: olodaterol 5 µg QD; olodaterol 10 µg QD; formoterol BID; placebo QD